Imperial College London
Portrait Picture

Professor Cleo Kontoravdi

Faculty of Engineering, Department of Chemical Engineering

Professor of Biological Systems Engineering
 
 
 
//

Contact

 

+44 (0)20 7594 6655cleo.kontoravdi98 Website

 
 
//

Location

 

310ACE ExtensionSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Palmieri:2022:10.3390/vaccines10071034,
author = {Palmieri, E and Kis, Z and Ozanne, J and Di, Benedetto R and Ricchetti, B and Massai, L and Carducci, M and Oldrini, D and Gasperini, G and Aruta, MG and Rossi, O and Kontoravdi, C and Shah, N and Mawas, F and Micoli, F},
doi = {10.3390/vaccines10071034},
journal = {Vaccines},
pages = {1--17},
title = {GMMA as an alternative carrier for a glycoconjugate vaccine against Group A streptococcus},
url = {http://dx.doi.org/10.3390/vaccines10071034},
volume = {10},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Group A Streptococcus (GAS) causes about 500,000 annual deaths globally, and no vaccines are currently available. The Group A Carbohydrate (GAC), conserved across all GAS serotypes, conjugated to an appropriate carrier protein, represents a promising vaccine candidate. Here, we explored the possibility to use Generalized Modules for Membrane Antigens (GMMA) as an alternative carrier system for GAC, exploiting their intrinsic adjuvant properties. Immunogenicity of GAC-GMMA conjugate was evaluated in different animal species in comparison to GAC-CRM197; and the two conjugates were also compared from a techno-economic point of view. GMMA proved to be a good alternative carrier for GAC, resulting in a higher immune response compared to CRM197 in different mice strains, as verified by ELISA and FACS analyses. Differently from CRM197, GMMA induced significant levels of anti-GAC IgG titers in mice also in the absence of Alhydrogel. In rabbits, a difference in the immune response could not be appreciated; however, antibodies from GAC-GMMA-immunized animals showed higher affinity toward purified GAC antigen compared to those elicited by GAC-CRM197. In addition, the GAC-GMMA production process proved to be more cost-effective, making this conjugate particularly attractive for low- and middle-income countries, where this pathogen has a huge burden.
AU  - Palmieri,E
AU  - Kis,Z
AU  - Ozanne,J
AU  - Di,Benedetto R
AU  - Ricchetti,B
AU  - Massai,L
AU  - Carducci,M
AU  - Oldrini,D
AU  - Gasperini,G
AU  - Aruta,MG
AU  - Rossi,O
AU  - Kontoravdi,C
AU  - Shah,N
AU  - Mawas,F
AU  - Micoli,F
DO  - 10.3390/vaccines10071034
EP  - 17
PY  - 2022///
SN  - 2076-393X
SP  - 1
TI  - GMMA as an alternative carrier for a glycoconjugate vaccine against Group A streptococcus
T2  - Vaccines
UR  - http://dx.doi.org/10.3390/vaccines10071034
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000834389700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2076-393X/10/7/1034
UR  - http://hdl.handle.net/10044/1/99381
VL  - 10
ER  -
Download